David Fermin is a Cardiology physician affiliated with Grand Rapids Community College. OpenAlex indexes 60 publications with 2,100 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2902 Bradford St NE
Grand Rapids, MI 49525
Telephone
616-885-5200Provider last certified this registry record 9 Sept 2021.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202530 payments$37,960openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202510 payments
- Abbott LaboratoriesProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.9%Aldosterone antagonist (MRA)16.7%Spironolactone89%Eplerenone11%Part D≥168 patientsBeta blocker14.3%Metoprolol Succinate66%Carvedilol28%Metoprolol Tartrate6%Part D<11 patients+ 12 more classes in this area
Metabolism & gastrointestinal
13.6%SGLT2 inhibitor11.1%Farxiga64%Jardiance36%Part D≥51 patientsPotassium supplement2.1%Potassium Chloride100%Part D≥24 patients+ 1 more class in this area
Nervous system
9.9%Other nervous system drugs9.9%Vyndamax100%Part D≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 26-A-17871-ACC PROGNOSTIC IMPLICATIONS OF ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS ON TAFAMIDIS
Journal of the American College of Cardiology
2026 - 26-A-18174-ACC RACE-BASED DISPARITIES IN ADVANCED HEART FAILURE (AHF) EVALUATION AND OUTCOMES
Journal of the American College of Cardiology
2026 - Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology
2025 - Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial
Circulation Genomic and Precision Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Tomasz Timek, MD
Grand Rapids Community College
Barbara Pickut, MD
Grand Rapids Community College
David Wohns, MD
Grand Rapids Community College
Troy Quigg, DO
Grand Rapids Community College
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”